{"id":"relugolix-120-mg-orgovyx","_chembl":{"chemblId":"CHEMBL1800159","moleculeType":"Small molecule","molecularWeight":"623.64"},"allNames":"relugolix 120 mg [orgovyx]","_dailymed":null,"mechanism":{"target":"GnRH","drugClass":"GnRH receptor antagonist","explanation":"Relugolix works by blocking the GnRH receptor in the pituitary gland, which decreases the levels of hormones that stimulate the ovaries or testes, leading to reduced sex hormone levels.","oneSentence":"Relugolix binds to and inhibits the gonadotropin-releasing hormone (GnRH) receptor, reducing the production of luteinizing hormone and follicle-stimulating hormone."},"_scrapedAt":"2026-03-28T01:47:52.311Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:46:18.935198+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06111781","phase":"PHASE2","title":"The SUGAR Study; SBRT and Relugolix) for Prostate Cancer","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-04-15","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT05605964","phase":"PHASE3","title":"Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2023-01-25","conditions":"Prostate Cancer","enrollment":387},{"nctId":"NCT05467176","phase":"","title":"A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-10-04","conditions":"Prostate Cancer","enrollment":999},{"nctId":"NCT07069465","phase":"EARLY_PHASE1","title":"Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging","status":"COMPLETED","sponsor":"Urology Clinics of North Texas","startDate":"2024-06-15","conditions":"Prostate Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Relugolix 120 MG [Orgovyx]","genericName":"relugolix-120-mg-orgovyx","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:46:18.935198+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}